Luspatercept for MDS Anemia: Real-World Evidence
Luspatercept is proving to be a more effective initial treatment for anemia in patients wiht lower-risk myelodysplastic syndromes (LR-MDS) than conventional methods, according to a recent real-world study. Researchers found that patients using luspatercept achieved faster and more sustained red blood cell transfusion independence. The study, backing up FDA approval, showed impressive results: 89.1% saw a hemoglobin increase within six months. This news, reported by News Directory 3, reinforces luspatercept’s potential as a first-line standard treatment. discover what’s next for patients benefiting from this innovative approach.
Luspatercept Shows Promise for MDS Anemia Treatment
Updated June 06, 2025
Luspatercept may offer a more effective initial treatment for anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) compared to erythropoiesis-stimulating agents (ESAs). These findings, presented at the 2025 American Society of Clinical Oncology annual meeting, stem from a real-world study evaluating the drug’s performance.
The study supports the FDA’s August 2023 approval of luspatercept, which was based on the COMMANDS trial. That trial demonstrated that 58.5% of LR-MDS patients at risk of anemia achieved transfusion independence for 12 weeks with luspatercept, versus 31.2% with ESAs.
Traditionally, ESAs like epoetin alfa or darbepoetin have been the primary treatment for anemia in MDS, working by stimulating red blood cell production.Luspatercept, though, functions as a recombinant fusion protein, enhancing erythropoiesis in its later stages.
The real-world analysis examined 103 LR-MDS patients who received either luspatercept (n = 46) or ESAs (n = 57) as their initial therapy between August 2023 and july 2024. Researchers retrospectively reviewed patient data from October to December 2024.
After a median follow-up of approximately eight months, 89.1% of luspatercept patients experienced a hemoglobin increase of at least 1.5 g/dL within six months, compared to 56.1% in the ESA group. moreover, sustained improvement, defined as maintaining that hemoglobin increase for at least eight weeks, was more prevalent in the luspatercept group (80.4% vs 47.4%).
The study also revealed that luspatercept led to quicker and more durable red blood cell transfusion independence. Among patients who needed transfusions at the start,91.7% of those on luspatercept achieved independence within three months, compared to 71.4% on ESAs. The luspatercept group also reached independence faster, with a median of 0.8 months versus 1.9 months, and maintained it for at least 12 weeks more often (91.7% vs 64.3%).
Additionally, the luspatercept cohort demonstrated a greater mean hemoglobin gain over six months (1.7 g/dL vs 1.0 g/dL) and a higher proportion of patients with a 50% or greater reduction in transfusion needs (75% vs 42.9%).
“During the first 6 months of treatment, a higher proportion of patients receiving first-line luspatercept showed improvement in [hemoglobin] and a reduced need for RBC compared to those receiving first-line ESA,” the authors concluded.
The researchers added that their analysis reinforces the COMMANDS trial results, highlighting the favorable real-world effectiveness of luspatercept as a first-line treatment for anemia in LR-MDS.
What’s next
These findings are expected to further solidify luspatercept’s role in routine clinical practice for managing anemia in patients with lower-risk myelodysplastic syndromes.